Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms on their most important mergers, acquisitions and takeover transactions.
Paul, Weiss Recognized for Two Impact Deals in 2024 LMG Life Sciences Americas Awards
- Awards
- September 6, 2024
Practices
- Mergers & Acquisitions
- Corporate
- IP & Technology Transactions
- Executive Compensation
- Tax
- Litigation
- Antitrust
People
- Goodchild, Benjamin
- Veeraraghavan, Krishna
- Janson, Brian M.
- Kaoutzanis, Christodoulos
- Shim, Suhan
- Vaz de Almeida, Patricia
- Mi, Frances F.
- Ashtor, Jonathan H.
- Wahlquist Brown, Andrea K.
- Falik, Reuven
- Goldberger, Bruce N.
- Fox, Meghan E.
- Krause, Brian
- Chepiga, Geoffrey R.
- Bouchard, Andre G.
- Lohmann Parker, Crystal
- Juceam, Daniel J.
- O'Loughlin, Robert J.
- Sher, Scott A.
- Hahn, Todd
- McGee, Alexander S.
- Becker, Brynne C.
- Kang, Dan
- Mackie, Keith M.
- Zhuang, Yihan
- McLoughlin, Jean M.
- Belinkie, Sasha
- Kennedy, Richard N.
- Anderson, Annie
- Kennedy, Dana L.
- Rucker, Thomas "Tommy"
- Chitrao, Neil
- McDonough, Marissa A.
- Soven, Joshua H.
- Kelly, Marta P.
- de Souza, Chad
- Tam, Taylor
- Haase, Timothy M.
LMG Life Sciences named Paul, Weiss a winner of two “Impact Deal of the Year” awards as part of its 2024 LMG Life Sciences Americas Awards for our work advising Inhibrx in its $2.2 billion spin-off merger with Sanofi and GSK in its all-cash acquisition of BELLUS Health for approximate total equity value of $2 billion. The annual awards recognize leading law firms and attorneys in the life sciences industry across the United States, Canada and Brazil.
The Paul, Weiss team on the Inhibrx matter was led by corporate partners Benjamin Goodchild and Krishna Veeraraghavan and included partners Brian Janson, Christodoulos Kaoutzanis, Suhan Shim and Patricia Vaz de Almeida, and counsel Frances Mi; intellectual property partner Jonathan Ashtor; executive compensation partners Andrea Wahlquist Brown and Reuven Falik, and counsel Bruce Goldberger and Meghan Fox; tax partner Brian Krause; litigation partners Geoffrey Chepiga, Andre Bouchard and Crystal Parker, and counsel Daniel Juceam and Robert O'Loughlin; and antitrust partner Scott Sher and counsel Todd Hahn.
The Paul, Weiss team on the GSK matter includes, among others, corporate partners Krishna Veeraraghavan and Benjamin Goodchild, and associates Scott McGee, Brynne Becker, Dan Kang, Keith Mackie and Yihan Zhuang; executive compensation partner Jean McLoughlin, counsel Sasha Belinkie and associates Richard Kennedy and Annie Anderson; litigation associates Dana Kennedy, Thomas Rucker and Neil Chitrao; intellectual property partner Jonathan Ashtor and associate Marissa McDonough; antitrust partners Joshua Soven and Marta Kelly, and counsel Chad de Souza; and tax associates Taylor Tam and Timothy Haase.